NetraMark Corp. and Juvenescence Ltd. launch joint venture, using artificial intelligence to fight aging-related conditions

Tuesday, November 27, 2018 Anti-Aging News
Email Print This Page Comment bookmark
Font : A-A+

TORONTO, Nov. 27, 2018 /CNW/ - Toronto-based machine learning startup NetraMark Corp. and

UK biotech company Juvenescence Ltd. have partnered to form NetraPharma, a joint venture that is using artificial intelligence technologies to develop therapies that could slow, halt or potentially reverse aging.

Juvenescence sees incredible

potential for NetraMark's augmented intelligence technology to help Juvenescence attain its vision of eliminating the hardships caused by diseases associated with the aging process.

"The emerging longevity sector will show us lucrative opportunities like never before, and NetraPharma is a key piece of our vision," said Jim Mellon, the celebrated British investor who helped co-found Juvenescence. "Their insights and technological innovations advance our mission through improving clinical trial design in drug development, along with resurrecting failed drugs."

NetraMark's novel machine learning paradigm, NetraAI, helps pharmaceutical companies by using human expertise and machine intelligence to discover new drug targets and to build actionable models for placebo and drug response at the individual patient level. By extracting hidden information from failed or failing clinical trials, the technology has the potential to revive drugs that could help millions of people.

"NetraMark's AI engine generates a keen understanding of how patient sub-populations respond to therapeutics.  Netramark's technology will form an important part of a future in which we can precisely match specific drugs to the right patient to treat their conditions. Machine intelligence strategies to develop personalized therapeutics will be transformative to the practice of medicine and to clinical outcome in patients," said Dr. Greg Bailey, CEO of Juvenescence and one of the founding partners of the newly-formed NetraPharma joint venture along with Juvenescence COO Alexander Pickett and Juvenescence co-founder Dr. Declan Doogan.

NetraMark was founded in 2015 by Dr. Joseph Geraci, a Canadian mathematician, medical scientist, and quantum machine learning specialist who was joined by COO Richard Brooks, a business lawyer and serial entrepreneur who has supported Canadian startups for more than 20 years.

ABOUT NETRAMARK:NetraMark is a Toronto-based AI company with dedicated solutions for pharmaceutical companies, with a unique machine learning platform for drug development, stratification, personalization, placebo response prediction, drug resurrection and repurposing. The technical AI paradigm was discovered by CEO Dr. Joseph Geraci, a mathematician, medical scientist, and quantum machine learning specialist who began commercializing the idea in 2015 with the help of COO Richard Brooks, a business lawyer and serial entrepreneur who has supported Canadian startups for more than 20 years. For more information, please visit

ABOUT JUVENESCENCE LIMITED:Juvenescence Limited is a life science and biotech company developing therapies to increase healthy human longevity. It was founded in 2016 by Jim Mellon, Dr. Greg Bailey, Dr. Declan Doogan, Anthony Chow, and Alexander Pickett. The Juvenescence team are highly experienced drug developers, entrepreneurs and investors with a significant history of success in the life sciences sector. Juvenescence will create, partner with or invest in new companies with aging or age-related therapeutics, by in-licensing compounds from academia and industry, or forming joint ventures to develop therapeutics for longevity. Juvenescence believes that recent advances in science have greatly improved our understanding of the biology of aging and seeks to develop therapeutics with the possibility of slowing, halting or potentially reversing elements of aging. Further details regarding Juvenescence and its operations and investments are set out at

SOURCE NetraMark Corp.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store